OR WAIT null SECS
August 13, 2020
ANA will use Quotient’s formulation and manufacturing knowledge to develop and supply the drug product for clinical trials by the third quarter of 2020.
In combination with BARDA’s previous award, the commitment for early access to Moderna’s vaccine candidate has now reached to up to $2.48 billion.
Atomwise’s technology, AtomNet, works to eliminate the barriers of physical screening for small molecule drug discovery.
August 12, 2020
The companies will work to establish an operational footprint across North America and Europe that will offer customers supply chain assurance for a combined portfolio of leading solutions.
The company will use the acquisition to further its drug development pipeline in women’s healthcare.
August 11, 2020
The companies will collaborate on the manufacturing, clinical development, and regulatory activities for Novavax’s COVID-19 vaccine in Japan.
The CDMO will offer capacity for manufacturing and distributing COVID-19 vaccines and therapeutics at its Grand Rapids, MI, fill/finish facility.
August 07, 2020
Sanofi and GlaxoSmithKline have been selected to supply the US government and the European Union with millions of doses of their COVID-19 vaccine candidate.
The company is working to ensure broad global access to its COVID-19 vaccine candidate, following approval from regulators.
The companies have agreements to supply its mRNA-based COVID-19 vaccine to Japan and Canada, pending regulatory approvals in those countries.